Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: An evidence-based review

Drugs

Volumn 73, Issue 12, 2013, Pages 1307-1319

  Lingman Framme, Jenny ^a   Fasth, Anders ^b  

^a Halland Hospital   (Sweden)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

BACTERIAL INFECTION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALTH ECONOMICS; HUMAN; IMMUNE DEFICIENCY; PATIENT PREFERENCE; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW;

ADMINISTRATION, INTRAVENOUS; COST-BENEFIT ANALYSIS; HOME CARE SERVICES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, SUBCUTANEOUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84883252281     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0094-3     Document Type: Review

References (82)

1. Cohn EJ, Oncley JL, Strong LE, et al. Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma. J Clin Invest. 1944;23:417-32.
2. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722-8.
3. Bruton OC. A decade with agammaglobulinemia. J Pediatr. 1962;60:672-6.
4. Record BR, Gunn W, et al. Human gammaglobulin. Br Med J. 1946;1:101.
5. Eijkhout HW, van der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135:165-74.
6. Ochs HD, Fischer SH, Wedgwood RJ, et al. Comparison of high dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med. 1984;76:78-82.
7. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1:1075-7.
8. Slade HB. Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol. 1994;1:613-9.
9. Gardulf A, Hammarström L, Smith CI. Home treatment of hypogamma-globulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162-6.
10. Guidelines for diagnosis and treatment of primary immunodeficiency [in Swedish)], 3rd ed. 2011. http://www.slipi.nu/klinik/Broschyr-Riktlinjer-V3-2011. pdf.
11. Guidelines for diagnosis and treatment of primary immunodeficiency [in Danish], 2nd ed. 2013. ISBN 978-87-92568-01-4 http://www.immundefekt-diagnostik. dk.
12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi: 10.1371/journal.pmed.1000100.
13. Food and Drug Administration. Guidance for industry safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. 2008. http://www.fda.gov/cber/guidelines.htm.
14. Chapel HM. Consensus on diagnosis and management of primary antibody deficiencies. BMJ. 1994;308:581-5.
15. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. J Clin Immunol. 2004;112:1-7.
16. Chinen J, Shearer WT. Subcutaneous immunoglobulins: alternative for the hypogammaglobulinemic patient? J Allergy Clin Immunol. 2004;114:934-5.
17. Busse J, Hoffman F, Schlieben S, et al. Subcutaneous immunoglobulin substitution in primary B-cell defects. Review of the literature and experiences with 17 patients over a period of 6 years [in German]. Tagliche Praxis. 2005;46:185-92.
18. Chouksey A, Duff K, Wasserbauer N, et al. Subcutaneous immunoglobulin-G replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin Immunol. 2005;1:120-30.
19. Durandy A, Wahn V, Petteway S, et al. Immunoglobulin replacement therapy in primary antibody deficiency diseases: maximizing success. Int Arch Allergy Immunol. 2005;136:217-29.
20. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006;6:434-42.
21. Hernandez M, Bastian JF. Immunodeficiency in childhood. Curr Allergy Asthma Rep. 2006;6:468-74.
22. Helbert M, Farragher A. Subcutaneous immunoglobulin for patients with antibody deficiency. Br J Hosp Med (Lond). 2007;68:206-10.
23. Ballow M. Immunoglobulin therapy: methods of delivery. J Allergy Clin Immunol. 2008;122:1038-9.
24. Berger M. Principles and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin N Am. 2008;28:413-37.
25. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin N Am. 2008;28:803-19.
26. st century. Ann Allergy Asthma Immunol. 2008;101:114-21.
27. Stiehm ER, Keller MA, Vyas GN. Preparation and use of therapeutic antibodies primarily of human origin. Biologicals. 2008;36:363-74.
28. Kirmse J. The nurse's role in intravenous immunoglobulin therapy. Home Healthc Nurse. 2009;27:104-11.
29. Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158:51-9.
30. Moore ML, Quinn JM. Subcutaneous immunoglobulin therapy in pediatric primary antibody deficiency. Ped Health. 2009;3:231-40.
31. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125:182-94.
32. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11:532-8.
33. Hoernes M, Seger R, Reichenbach J. Modern management of primary B-cell immunodeficiencies. Pediatr Allergy Immunol. 2011;22:758-69.
34. Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents. 2011;37:396-404.
35. Misbah S, Kuijpers T, van der Heijden J, et al. Bringing immunoglobulin knowledge up to date: how should we treat today? Clin Exp Immunol. 2011;166:16-25.
36. Rezaei N, Abolhassani H, Aghamohammadi A, et al. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol. 2011;7:301-16.
37. Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32:1180-92.
38. Borte M, Baumann U, Pittrow D, et al. Immunoglobulins in PID, SID and neurological autoimmune disease [in German]. Dtsch Med Wochenschr. 2012;137:675-80.
39. Haddad E, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci. 2012;46:315-21.
40. Hernandez-Trujillo HS, Chapel H, Lo Re V, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol. 2012;169:57-69.
41. Kobrinsky L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277-87.
42. Atkins D, Best D, Briss PA, GRADE Working Group, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490-4.
43. Schünemann H, Brożek J, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 (updated March 2009). The GRADE Working Group, 2009. Available from http://www.cc-ims. net/gradepro.
44. Checklist from SBU regarding randomized controlled trials http://www.sahlgrenska.se/upload/SU/HTA-centrum/ Hj%c3%a4lpmedel%20under%20projektet/B02- Granskningsmall%20f%c3%b6r%20randomiserad%20kontrollerad%20pr%c3%b6vning.doc. [Accessed 2012 Jan 03].
45. Checklist from SBU regarding cohort studies. Version 2010:1. http://www.sahlgrenska.se/upload/SU/HTA-centrum/ Hj%c3%a4lpmedel%20under%20projektet/1/B03- Granskningsmall%20f%c3%b6r%20kohortstudier%20med%20kontrollgrupp%20modifierad%2 0OS%20IT.doc. [Accessed 2012 Jan 03].
46. Checklist from SBU regarding economic studies. Version 2012:1 http://www.sbu.se/upload/ebm/metodbok/Mall-modell-halsoekonomi.pdf. [Accessed 2012 Jan 03].
47. Gardulf A, Andersen V, Björkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365-9.
48. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48-51.
49. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94-100.
50. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114:936-42.
51. Högy B, Keinecke H, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ. 2005;6:24-9.
52. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65-72.
53. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies: a prospective, multi-national study. J Clin Immunol. 2006;26:177-85.
54. Haddad L, Perrinet M, Parent D, et al. Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution [in French]. Rev Med Interne. 2006;27:924-6.
55. Kittner JM, Grimbacher B, Wulff W, et al. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006;26:400-5.
56. Ochs HD, Gupta S, Kiessling P, Subcutaneous IgG Study Group, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265-73.
57. Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007;96:1474-8.
58. Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28:370-8.
59. Desai SH, Chouksey A, Poll J, et al. Pilot study of equal doses of 10 % IGIV given intravenously or subcutaneously. J Allergy Clin Immunol. 2009;124:854-6.
60. Maroto Hernando M, Soler Palacín P, Martin Nalda N, et al. Subcutaneous gammaglobulin in common variable immunodeficiency: first experience in Spain [in Spanish]. An Pediatr 2009;70:111-9.
61. Beauté J, Levy P, Millet V, French PID study group CEREDIH, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160:240-5.
62. Hoffmann F, Grimbacher B, Thiel J, et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010;15:238-45.
63. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. Clin Immunol. 2010;30:301-7.
64. Wasserman RL, Irani AM, Tracy J, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10 % caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161:518-26.
65. ® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol. 2011;141:90-102.
66. Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10 % liquid immune globulin preparation (GAMMAGARD LIQUID, 10 %) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31:323-31.
67. Wasserman RL, Melamed I, Nelson RP Jr, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50:405-11.
68. Sundin M, Nordin K, Jostemyr Y, et al. Subcutaneous IgG replacement after pediatric SCT. Pediatric Transpl. 2012;16:866-71.
69. Wasserman RL, Melamed I, Stein MR, et al. IGSC, 10 % with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130:951-7.
70. Martin A, Lavoie L, Goetghebeur M, et al. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23:55-60.
71. Ducruet T, Levasseur MC, Des Roches A, et al. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol. 2013;131:585-7.
72. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525-53.
73. Gennery AR, Slatter MA, Grandin L, on behalf of members of European Group for Blood and Marrow Transplantation and European Society for Immunodeficiency, et al. Long term survival and transplantation of haematopoietic stem cells for primary immunodeficiencies: report of the European experience 1968-2005. J Allergy Clin Immunol. 2010;126:602-10.
74. Eapen M, Ahn KW, Orchard PJ, et al. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biol Blood Marrow Transpl. 2012;18:1438-45.
75. Caress JB, Hobson-Webb L, Passmore LV. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol. 2009;256:339-42.
76. Al-Riyami AZ, Lee J, Connolly M, et al. Cerebral sinus thrombosis following IV immunoglobulin therapy of immune thrombocytopenia purpura. Pediatr Blood Cancer. 2011;57:157-9.
77. FDA Safety Communication: New boxed warning for thrombosis related to human immune globulin products. 2013. http://www.fda.gov/BiologicsBloodVaccines/ SafetyAvailability/ucm355986.htm.
78. European Medicines Agency. Hizentra. Product information. EMEA/H/C/002127-II/0020/G. 2013 http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/002127/human-med-001440.jsp&mid= WC0b01ac058001d124.
79. Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21-30.
80. Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169:172-81.
81. Berger M, Jolles S, Orange JS, et al. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol. 2013;33:984-90.
82. Huang F, Feuille E, Cunningham-Rundles C. Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States. J Clin Immunol. 2013;33:49-54.